Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The major histocompatibility complex (MHC) is a set of cell surface proteins essential for the adaptive immune system. MHC molecules bind peptide fragments derived from pathogens or self-proteins and display them on the cell surface for recognition by T cells. In humans, the MHC is referred to as the human leukocyte antigen (HLA) system. The HLA gene cluster is located on chromosome 6p21.3. There are three main classes of genes: Class I, Class II, and Class III. Class I MHC molecules present endogenous peptides to CD8+ cytotoxic T cells, while Class II MHC molecules present exogenous peptides to CD4+ helper T cells. Class III encodes complement components and cytokines; not directly involved in peptide presentation. MHC genes are highly polymorphic, ensuring broad population-level protection against pathogens but also underlying tissue transplant rejection and influencing susceptibility or resistance to autoimmune diseases.
MHC molecules present peptide antigens to T cells, initiating adaptive immune responses. Drugs targeting MHC indirectly modulate these responses by affecting T cell activation or antigen presentation.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major Histocompatibility Complex Molecule (MHC).